Transient loss of Polycomb components induces an epigenetic cancer fateVictoria Parreno, Giacomo Cavalli, Chetan C. Rawal et al.|Nature|2024Cited by 147
PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDsLaurie Herviou, Jérôme Moreaux|Clinical Epigenetics|2018Cited by 47
Antioxidant Defenses Confer Resistance to High Dose Melphalan in Multiple Myeloma CellsClaire Gourzonès, Jérôme Moreaux|Cancers|2019Cited by 30
Identification of a 20-Gene Expression-Based Risk Score as a Predictor of Clinical Outcome in Chronic Lymphocytic Leukemia PatientsElias Bou Samra, Jérôme Moreaux|BioMed Research International|2014Cited by 20
Transient loss of Polycomb components induces an epigenetic cancer fateVictoria Parreno, Giacomo Cavalli, Vincent Loubière et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 12